As tumor cells multiply, they often spawn tens of thousands of genetic mutations. Figuring out which ones are the most promising to target with immunotherapy is like finding a few needles in a haystack. Now a new model developed ...
Oct 9, 2019
0
10
If you follow news about medical breakthroughs, you have undoubtedly heard about immunotherapy to treat cancer.
Oct 1, 2019
0
3
A team of researchers affiliated with a large number of institutions in Germany has tested several machine-learning algorithms to see how well they can identify the differences between lung tumors associated with head and ...
Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according ...
Sep 9, 2019
0
1
Researchers had previously reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based chemotherapy in untreated advanced nonsquamous non-small cell lung cancer patients. ...
Sep 8, 2019
0
4
Scientists have shown exactly how mutations in two different genes coordinate to drive the development of malignant lung tumors, according to a new report in the open-access journal eLife.
Aug 27, 2019
0
6
PD-1 is a protein on our T cells that normally keeps these immune cells from running amok. A growing number of cancer drugs are designed to inhibit PD-1, enabling patients' T-cells to attack and kill cancerous cells. PD-1 ...
Aug 27, 2019
0
97
Immunotherapy has revolutionized the treatment of cancer in the last decade, yet many tumors do not respond to these new therapies. A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates ...
Aug 23, 2019
0
114
Lung cancer is the second most common cancer found in both men and women. It is estimated there will be roughly 228,000 new lung cancer cases this year, and nearly 30% of those patients will have mutations in the KRAS pathway. ...
Aug 19, 2019
0
36
Changing the standard dose and timing of two therapies greatly cut tumor relapse and reduced side effects in mouse models of kinase mutated breast cancer and lung cancer, UT Southwestern Simmons Cancer Center researchers ...
Aug 9, 2019
0
35
